Podcast & CME Activities

CLICK ON STATES TO SEE LIVE ACTIVITIES

Podcast

Jun
30
Tue
COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care
Jun 30 2020 @ 7:19 am – Jun 30 2022 @ 8:19 am

COVID-19 Frontline Therapies:
Navigating Through This Health Crisis and Optimizing Patient Care

Download Toolkit

PROGRAM SPEAKER 

Brian Nyquist, MPH
President & CEO
National Infusion Center Association
Executive Director of the Infusion Access Foundation
Austin, TX

PROGRAM OVERVIEW

This COVID-19 FRONTLINE podcast provides an update to new monoclonal antibody infusion therapies approved for emergency use for the treatment of COVID-19. Each podcast focuses on different issues facing clinicians, such as managing patients with COVID-19, addressing the care of special populations during the pandemic, and other important topics.

TARGET AUDIENCE

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, and pharmacists across emergency medicine, primary care, family medicine, infusion centers, and the Department of Veteran Affairs.

LEARNING OBJECTIVE

On completing this program, attendees should be able to:

  • Assess the rationale for the use of new virus-neutralizing monoclonal antibodies to mitigate the risk of viral resistance to therapy
  • Develop in-clinic infusion capability to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care
  • Use guidance and resources developed to promote safe and responsible use of infusion therapies for treating patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST


Mr. Nyquist
has nothing to disclose.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Angela Davis, PhD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator, has nothing to disclose. 

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating in this online activity.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making experience before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITY ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]


Provided by Med Learning Group


Co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only.  Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Online Programs

Nov
20
Fri
COVID-19 Frontline TeleECHO Enduring: Evolving Strategies in the Management and Prevention of COVID-19
Nov 20 @ 9:00 am – 10:00 am

 

COVID-19 Frontline TeleECHO Series: Evolving Strategies in the Management and Prevention of COVID-19

VIEW ACTIVITY

 

Dec
23
Wed
COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Dec 23 @ 12:00 pm – 1:00 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

 

 

FACULTY

Michael Niederman MD, MACP, FCCP, FCCM, FERS
Associate Division Chief
Clinical Director, Pulmonary and Critical Care
New York Presbyterian/ Weill Cornell Medical Center
Professor of Clinical Medicine
Weill Cornell Medical College
New York, NY

PROGRAM OVERVIEW

This program will explore the use of agents recently granted emergency use authorization for the management of COVID-19. Clinicians will learn about the mechanism of action of monoclonal antibodies against COVID-19, how to identify patients who are at risk for developing severe COVID-19, and discuss best practices on incorporating these agents into clinical practice to prevent the development of severe COVID-19 in recently diagnosed patients. This activity will also explore the use of baricitinib in combination with remdesivir for patients hospitalized with COVID-19 and provide guidance on how to select patients who would benefit from this therapy.

TARGET AUDIENCE

This activity is designed to meet the educational needs of a variety of specialties, including infectious disease specialists, pulmonary medicine specialists, emergency room practitioners, advanced practitioners, nurses, and other healthcare professionals to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of dual neutralizing monoclonal antibody cocktail therapies recently granted emergency use authorizations (EUAs) for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live virtual activity for a maximum of 0.75 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the live virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 0.75 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 0.75 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Niederman has conducted research for Bayer, Merck, and Shionogi and is a consultant for Pfizer, Merck, Bayer, Thermo-Fisher, Nabriva, and N8 Medical.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this live virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based live activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: December 23, 2020

EXPIRATION DATE: December 23, 2021

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2020 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

Feb
3
Wed
Whiteboard series: Emerging Monoclonal Antibody Therapies and Vaccines for COVID-19: How They Work and When to Use Them
Feb 3 @ 8:16 am – 9:15 am

Whiteboard series: COVID-19 Frontline: Emerging Monoclonal Antibody Therapies and Vaccines for COVID-19: How They Work and When to Use Them

VIEW ACTIVITY

 

Mar
4
Thu
COVID-19 Frontline TeleECHO Enduring : COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Mar 4 2021 @ 12:00 am – Mar 4 2022 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

FACULTY


Shyam Kottilil, MD, PhD
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

PROGRAM OVERVIEW

The COVID-19 FRONTLINE TeleECHO program provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. This recorded TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19.

TARGET AUDIENCE

This activity is intended for pulmonologists, critical care specialists, infectious disease specialists, hospitalists, and hospital pharmacists to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of therapies recently granted EUAs for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtual activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Kottilil discloses that the University of Maryland has received funds to participate in trials, as well he has received research funds paid to the university from Merck Inc, Gilead Sciences and Arbutus Pharmaceuticals. He has also provided contracted research for Regeneron, Eli Lilly, and air Pharmaceuticals, as well as serving on the advisory board for hepatitis b functional cure program at Merck Inc.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this web-based virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: March 4, 2021

EXPIRATION DATE: March 4, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

 

TeleECHOs

Apr
20
Tue
COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 1:00 pm – 2:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

1:00PM – 2:00PM ET

Please note this TeleECHO program is 1:00PM Eastern, 12:00PM, Central, 11:00AM Mountain and 10:00AM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Roger Bedimo, MD, MS
Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 5:00 pm – 6:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

5:00PM – 6:00PM ET

Please note this TeleECHO program is 5:00PM Eastern, 4:00PM, Central, 3:00PM Mountain and 2:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Christopher Palma, MD, ScM
Assistant Professor of Medicine
University of Rochester
Rochester, NY

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

Apr
23
Fri
COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 23 @ 3:00 pm – 4:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Friday, April 23, 2021

3:00PM – 4:00PM ET

Please note this TeleECHO program is 3:00PM Eastern, 2:00PM, Central, 1:00PM Mountain and 12:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Shyam Kottilil, MD, PhD (PROGRAM CHAIR)
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

Apr
24
Sat
COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 24 @ 10:00 am – 11:00 am

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Saturday, April 24, 2021

10:00AM – 11:00AM ET

Please note this TeleECHO program is 10:00AM Eastern, 9:00AM, Central, 8:00AM Mountain and 7:00AM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Christopher Palma, MD, ScM
Assistant Professor of Medicine
University of Rochester
Rochester, NY

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

Apr
26
Mon
COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 26 @ 1:00 pm – 2:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Monday, April 26, 2021

1:00PM – 2:00PM ET

Please note this TeleECHO program is 1:00PM Eastern, 12:00PM, Central, 11:00AM Mountain and 10:00AM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

William A. Fischer II, MD
Associate Professor of Medicine, Pulmonary and Critical Care Medicine
Director of Emerging Pathogens
Institute for Global Health and Infectious Diseases
The University of North Carolina
Chapel Hill, NC

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 26 @ 6:00 pm – 7:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Monday, April 26, 2021

6:00PM – 7:00PM ET

Please note this TeleECHO program is 6:00PM Eastern, 5:00PM, Central, 4:00PM Mountain and 3:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

William A. Fischer II, MD
Associate Professor of Medicine, Pulmonary and Critical Care Medicine
Director of Emerging Pathogens
Institute for Global Health and Infectious Diseases
The University of North Carolina
Chapel Hill, NC

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

Apr
27
Tue
COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 27 @ 3:00 pm – 4:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 27, 2021

3:00PM – 4:00PM ET

Please note this TeleECHO program is 3:00PM Eastern, 2:00PM, Central, 1:00PM Mountain and 12:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

William A. Fischer II, MD
Associate Professor of Medicine, Pulmonary and Critical Care Medicine
Director of Emerging Pathogens
Institute for Global Health and Infectious Diseases
The University of North Carolina
Chapel Hill, NC

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 27 @ 6:00 pm – 7:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 27, 2021

6:00PM – 7:00PM ET

Please note this TeleECHO program is 6:00PM Eastern, 5:00PM, Central, 4:00PM Mountain and 3:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Shyam Kottilil, MD, PhD (PROGRAM CHAIR)
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

Apr
28
Wed
COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 28 @ 7:00 pm – 8:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Wednesday, April 28, 2021

7:00PM – 8:00PM ET

Please note this TeleECHO program is 7:00PM Eastern, 6:00PM, Central, 5:00PM Mountain and 4:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Christopher Palma, MD, ScM
Assistant Professor of Medicine
University of Rochester
Rochester, NY

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

May
7
Fri
COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care
May 7 @ 12:00 pm – 1:00 pm

COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care

REGISTER FOR ECHO SESSION

Friday, May 7, 2021

12:00PM – 1:00PM ET

Please note this TeleECHO program is 12:00PM Eastern, 11:00AM, Central, 10:00AM Mountain and 9:00AM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

William A. Fischer II, MD
Associate Professor of Medicine, Pulmonary and Critical Care Medicine
Director of Emerging Pathogens
Institute for Global Health and Infectious Diseases
The University of North Carolina
Chapel Hill, NC

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of new virus-neutralizing monoclonal antibodies to mitigate the risk of viral resistance to therapy
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care
  • Use guidance and resources developed to promote safe and responsible use of infusion therapies for treating patients with COVID-19

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, and pharmacists across emergency medicine, primary care, family medicine, infusion centers, and the Department of Veteran Affairs.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

REGISTER FOR ECHO SESSION

 

BOOTH TOUR

Jun
30
Tue
COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care
Jun 30 2020 @ 7:19 am – Jun 30 2022 @ 8:19 am

COVID-19 Frontline Therapies:
Navigating Through This Health Crisis and Optimizing Patient Care

Download Toolkit

PROGRAM SPEAKER 

Brian Nyquist, MPH
President & CEO
National Infusion Center Association
Executive Director of the Infusion Access Foundation
Austin, TX

PROGRAM OVERVIEW

This COVID-19 FRONTLINE podcast provides an update to new monoclonal antibody infusion therapies approved for emergency use for the treatment of COVID-19. Each podcast focuses on different issues facing clinicians, such as managing patients with COVID-19, addressing the care of special populations during the pandemic, and other important topics.

TARGET AUDIENCE

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, and pharmacists across emergency medicine, primary care, family medicine, infusion centers, and the Department of Veteran Affairs.

LEARNING OBJECTIVE

On completing this program, attendees should be able to:

  • Assess the rationale for the use of new virus-neutralizing monoclonal antibodies to mitigate the risk of viral resistance to therapy
  • Develop in-clinic infusion capability to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care
  • Use guidance and resources developed to promote safe and responsible use of infusion therapies for treating patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST


Mr. Nyquist
has nothing to disclose.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Angela Davis, PhD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator, has nothing to disclose. 

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating in this online activity.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making experience before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITY ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]


Provided by Med Learning Group


Co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only.  Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Mar
4
Thu
COVID-19 Frontline TeleECHO Enduring : COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Mar 4 2021 @ 12:00 am – Mar 4 2022 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

FACULTY


Shyam Kottilil, MD, PhD
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

PROGRAM OVERVIEW

The COVID-19 FRONTLINE TeleECHO program provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. This recorded TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19.

TARGET AUDIENCE

This activity is intended for pulmonologists, critical care specialists, infectious disease specialists, hospitalists, and hospital pharmacists to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of therapies recently granted EUAs for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtual activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Kottilil discloses that the University of Maryland has received funds to participate in trials, as well he has received research funds paid to the university from Merck Inc, Gilead Sciences and Arbutus Pharmaceuticals. He has also provided contracted research for Regeneron, Eli Lilly, and air Pharmaceuticals, as well as serving on the advisory board for hepatitis b functional cure program at Merck Inc.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this web-based virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: March 4, 2021

EXPIRATION DATE: March 4, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

 

Apr
20
Tue
Grand Rounds @ East Meadow, NY
Apr 20 @ 12:00 pm – 1:00 pm

Date
Tuesday, April 20
12:00 – 1:00 PM

Location
Nassau University Medical Center
East Meadow, NY

Confirmed Speaker
Shyam Kottilil, MD, PhD

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 1:00 pm – 2:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

1:00PM – 2:00PM ET

Please note this TeleECHO program is 1:00PM Eastern, 12:00PM, Central, 11:00AM Mountain and 10:00AM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Roger Bedimo, MD, MS
Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 5:00 pm – 6:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

5:00PM – 6:00PM ET

Please note this TeleECHO program is 5:00PM Eastern, 4:00PM, Central, 3:00PM Mountain and 2:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Christopher Palma, MD, ScM
Assistant Professor of Medicine
University of Rochester
Rochester, NY

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

GRAND ROUNDS

Apr
20
Tue
Grand Rounds @ East Meadow, NY
Apr 20 @ 12:00 pm – 1:00 pm

Date
Tuesday, April 20
12:00 – 1:00 PM

Location
Nassau University Medical Center
East Meadow, NY

Confirmed Speaker
Shyam Kottilil, MD, PhD

Apr
21
Wed
Grand Rounds @ Brooklyn, NY
Apr 21 @ 1:15 pm – 2:15 pm

Date
Wednesday, April 21
1:15 – 2:15 PM

Location
Maimonides Medical Center Cancer Center
Brooklyn, NY

Confirmed Speaker
Timothy Albertson, MD, MPH, PhD

Apr
28
Wed
Grand Rounds @ Meadowbrook, PA
Apr 28 @ 12:00 pm – 1:00 pm

Date
Wednesday, April 28
12:00 – 1:00 PM

Location
Holy Redeemer
Meadowbrook, PA

Confirmed Speaker
Shyam Kottilil, MD, PhD

Apr
29
Thu
Grand Rounds @ Rockville, MD
Apr 29 @ 12:30 pm – 1:30 pm

Date
Thursday, April 29
12:30 – 1:30 PM

Location
Shady Grove Medical Center
Rockville, MD

Confirmed Speaker
Richard Martinello, MD

Jun
30
Tue
COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care
Jun 30 2020 @ 7:19 am – Jun 30 2022 @ 8:19 am

COVID-19 Frontline Therapies:
Navigating Through This Health Crisis and Optimizing Patient Care

Download Toolkit

PROGRAM SPEAKER 

Brian Nyquist, MPH
President & CEO
National Infusion Center Association
Executive Director of the Infusion Access Foundation
Austin, TX

PROGRAM OVERVIEW

This COVID-19 FRONTLINE podcast provides an update to new monoclonal antibody infusion therapies approved for emergency use for the treatment of COVID-19. Each podcast focuses on different issues facing clinicians, such as managing patients with COVID-19, addressing the care of special populations during the pandemic, and other important topics.

TARGET AUDIENCE

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, and pharmacists across emergency medicine, primary care, family medicine, infusion centers, and the Department of Veteran Affairs.

LEARNING OBJECTIVE

On completing this program, attendees should be able to:

  • Assess the rationale for the use of new virus-neutralizing monoclonal antibodies to mitigate the risk of viral resistance to therapy
  • Develop in-clinic infusion capability to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care
  • Use guidance and resources developed to promote safe and responsible use of infusion therapies for treating patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST


Mr. Nyquist
has nothing to disclose.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Angela Davis, PhD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator, has nothing to disclose. 

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating in this online activity.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making experience before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITY ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]


Provided by Med Learning Group


Co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only.  Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Mar
4
Thu
COVID-19 Frontline TeleECHO Enduring : COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Mar 4 2021 @ 12:00 am – Mar 4 2022 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

FACULTY


Shyam Kottilil, MD, PhD
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

PROGRAM OVERVIEW

The COVID-19 FRONTLINE TeleECHO program provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. This recorded TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19.

TARGET AUDIENCE

This activity is intended for pulmonologists, critical care specialists, infectious disease specialists, hospitalists, and hospital pharmacists to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of therapies recently granted EUAs for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtual activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Kottilil discloses that the University of Maryland has received funds to participate in trials, as well he has received research funds paid to the university from Merck Inc, Gilead Sciences and Arbutus Pharmaceuticals. He has also provided contracted research for Regeneron, Eli Lilly, and air Pharmaceuticals, as well as serving on the advisory board for hepatitis b functional cure program at Merck Inc.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this web-based virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: March 4, 2021

EXPIRATION DATE: March 4, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

 

Apr
20
Tue
Grand Rounds @ East Meadow, NY
Apr 20 @ 12:00 pm – 1:00 pm

Date
Tuesday, April 20
12:00 – 1:00 PM

Location
Nassau University Medical Center
East Meadow, NY

Confirmed Speaker
Shyam Kottilil, MD, PhD

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 1:00 pm – 2:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

1:00PM – 2:00PM ET

Please note this TeleECHO program is 1:00PM Eastern, 12:00PM, Central, 11:00AM Mountain and 10:00AM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Roger Bedimo, MD, MS
Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 5:00 pm – 6:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

5:00PM – 6:00PM ET

Please note this TeleECHO program is 5:00PM Eastern, 4:00PM, Central, 3:00PM Mountain and 2:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Christopher Palma, MD, ScM
Assistant Professor of Medicine
University of Rochester
Rochester, NY

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

A Virtual Reality Learning Experience: Integrating GLP-1 Receptor Agonists into T2DM Practice—Why, When, and How

Jun
30
Tue
COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care
Jun 30 2020 @ 7:19 am – Jun 30 2022 @ 8:19 am

COVID-19 Frontline Therapies:
Navigating Through This Health Crisis and Optimizing Patient Care

Download Toolkit

PROGRAM SPEAKER 

Brian Nyquist, MPH
President & CEO
National Infusion Center Association
Executive Director of the Infusion Access Foundation
Austin, TX

PROGRAM OVERVIEW

This COVID-19 FRONTLINE podcast provides an update to new monoclonal antibody infusion therapies approved for emergency use for the treatment of COVID-19. Each podcast focuses on different issues facing clinicians, such as managing patients with COVID-19, addressing the care of special populations during the pandemic, and other important topics.

TARGET AUDIENCE

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, and pharmacists across emergency medicine, primary care, family medicine, infusion centers, and the Department of Veteran Affairs.

LEARNING OBJECTIVE

On completing this program, attendees should be able to:

  • Assess the rationale for the use of new virus-neutralizing monoclonal antibodies to mitigate the risk of viral resistance to therapy
  • Develop in-clinic infusion capability to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care
  • Use guidance and resources developed to promote safe and responsible use of infusion therapies for treating patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST


Mr. Nyquist
has nothing to disclose.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Angela Davis, PhD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator, has nothing to disclose. 

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating in this online activity.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making experience before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITY ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]


Provided by Med Learning Group


Co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only.  Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Mar
4
Thu
COVID-19 Frontline TeleECHO Enduring : COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Mar 4 2021 @ 12:00 am – Mar 4 2022 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

FACULTY


Shyam Kottilil, MD, PhD
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

PROGRAM OVERVIEW

The COVID-19 FRONTLINE TeleECHO program provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. This recorded TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19.

TARGET AUDIENCE

This activity is intended for pulmonologists, critical care specialists, infectious disease specialists, hospitalists, and hospital pharmacists to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of therapies recently granted EUAs for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtual activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Kottilil discloses that the University of Maryland has received funds to participate in trials, as well he has received research funds paid to the university from Merck Inc, Gilead Sciences and Arbutus Pharmaceuticals. He has also provided contracted research for Regeneron, Eli Lilly, and air Pharmaceuticals, as well as serving on the advisory board for hepatitis b functional cure program at Merck Inc.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this web-based virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: March 4, 2021

EXPIRATION DATE: March 4, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

 

Apr
20
Tue
Grand Rounds @ East Meadow, NY
Apr 20 @ 12:00 pm – 1:00 pm

Date
Tuesday, April 20
12:00 – 1:00 PM

Location
Nassau University Medical Center
East Meadow, NY

Confirmed Speaker
Shyam Kottilil, MD, PhD

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 1:00 pm – 2:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

1:00PM – 2:00PM ET

Please note this TeleECHO program is 1:00PM Eastern, 12:00PM, Central, 11:00AM Mountain and 10:00AM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Roger Bedimo, MD, MS
Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 5:00 pm – 6:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

5:00PM – 6:00PM ET

Please note this TeleECHO program is 5:00PM Eastern, 4:00PM, Central, 3:00PM Mountain and 2:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Christopher Palma, MD, ScM
Assistant Professor of Medicine
University of Rochester
Rochester, NY

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

Jun
30
Tue
COVID-19 Frontline Therapies: Navigating Through This Health Crisis and Optimizing Patient Care
Jun 30 2020 @ 7:19 am – Jun 30 2022 @ 8:19 am

COVID-19 Frontline Therapies:
Navigating Through This Health Crisis and Optimizing Patient Care

Download Toolkit

PROGRAM SPEAKER 

Brian Nyquist, MPH
President & CEO
National Infusion Center Association
Executive Director of the Infusion Access Foundation
Austin, TX

PROGRAM OVERVIEW

This COVID-19 FRONTLINE podcast provides an update to new monoclonal antibody infusion therapies approved for emergency use for the treatment of COVID-19. Each podcast focuses on different issues facing clinicians, such as managing patients with COVID-19, addressing the care of special populations during the pandemic, and other important topics.

TARGET AUDIENCE

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19, including physicians, NPs, PAs, nurses, and pharmacists across emergency medicine, primary care, family medicine, infusion centers, and the Department of Veteran Affairs.

LEARNING OBJECTIVE

On completing this program, attendees should be able to:

  • Assess the rationale for the use of new virus-neutralizing monoclonal antibodies to mitigate the risk of viral resistance to therapy
  • Develop in-clinic infusion capability to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care
  • Use guidance and resources developed to promote safe and responsible use of infusion therapies for treating patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This CME activity was planned and produced in accordance with the ACCME Essentials.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST


Mr. Nyquist
has nothing to disclose.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
Staff Planners and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Angela Davis, PhD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator, has nothing to disclose. 

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.

METHOD OF PARTICIPATION

There are no fees for participating in this online activity.

DISCLAIMER

Med Learning Group makes every effort to develop CE activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making experience before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at [email protected]
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITY ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]


Provided by Med Learning Group


Co-provided by Ultimate Medical Academy/Complete Conference Management (CCM).

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only.  Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

Jul
30
Thu
Supporting the Mental Health of Frontline Healthcare Workers
Jul 30 2020 @ 8:30 am – Jul 30 2021 @ 8:45 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Mental Health: Supporting Frontline Healthcare Workers

VIEW ACTIVITY

Aug
14
Fri
Social Issues in Management of COVID-19
Aug 14 2020 @ 12:00 am – Aug 14 2021 @ 12:00 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Social Issues: Identifying Social Barriers in the Management of COVID-19

VIEW ACTIVITY

Aug
31
Mon
Treatment Options: Evaluating Evidence for Emerging Agents
Aug 31 2020 @ 6:16 am – Aug 31 2021 @ 7:16 am

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Treatment Options: Evaluating Evidence for Emerging Agents

VIEW ACTIVITY

Sep
25
Fri
ICU Management: Managing Critically Ill Patients with COVID-19
Sep 25 2020 @ 3:36 pm – Sep 25 2021 @ 4:36 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: ICU Management: Managing Critically Ill Patients with COVID-19

VIEW ACTIVITY

Nov
13
Fri
Emerging Vaccines Against SARS-CoV-2
Nov 13 2020 @ 3:36 pm – Nov 13 2021 @ 11:59 pm

COVID-19 FRONTLINE: Evolving Strategies in the Management and Prevention of COVID-19

Topic: Vaccines: Preventing the Spread of COVID-19

VIEW ACTIVITY

Mar
4
Thu
COVID-19 Frontline TeleECHO Enduring : COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19
Mar 4 2021 @ 12:00 am – Mar 4 2022 @ 11:45 pm

COVID-19 Frontline – A New Light in the Darkness: Therapies Recently Granted Emergency Use Authorizations for Patients with COVID-19

VIEW ACTIVITY

FACULTY


Shyam Kottilil, MD, PhD
Professor of Medicine
Chief, Division of Infectious Diseases
Institute of Human Virology
University of Maryland
Baltimore, MD

PROGRAM OVERVIEW

The COVID-19 FRONTLINE TeleECHO program provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. This recorded TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19.

TARGET AUDIENCE

This activity is intended for pulmonologists, critical care specialists, infectious disease specialists, hospitalists, and hospital pharmacists to help support them in their effort to optimize care of patients with COVID-19.

LEARNING OBJECTIVES

Upon the completion of this program, attendees should be able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of therapies recently granted EUAs for patients with COVID-19

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this virtual activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the virtual activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the treatment of patients with COVID-19.
Credits: 1.0 ANCC Contact Hour.

CNE ACCREDITATION STATEMENT

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Kottilil discloses that the University of Maryland has received funds to participate in trials, as well he has received research funds paid to the university from Merck Inc, Gilead Sciences and Arbutus Pharmaceuticals. He has also provided contracted research for Regeneron, Eli Lilly, and air Pharmaceuticals, as well as serving on the advisory board for hepatitis b functional cure program at Merck Inc.

CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.

Staff, Planners, and Managers
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director for Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes for Med Learning Group, has nothing to disclose.
Lisa Crenshaw, Senior Program Manager for Med Learning Group, has nothing to disclose.
Russie Allen, Accreditation and Outcomes Coordinator for Med Learning Group, has nothing to disclose.
Morgan Kravarik, Program Coordinator for Med Learning Group, has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this web-based virtual activity. To receive CME/CNE credit participants must:

  1. Read the CME/CNE information and faculty disclosures.
  2. Participate in the web-based enduring activity.
  3. Submit the evaluation form to Med Learning Group.

You will receive your certificate upon completion.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact Med Learning Group at [email protected].

RELEASE DATE: March 4, 2021

EXPIRATION DATE: March 4, 2022

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/.

Copyright © 2021 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.

 

VIEW ACTIVITY

 

Apr
20
Tue
Grand Rounds @ East Meadow, NY
Apr 20 @ 12:00 pm – 1:00 pm

Date
Tuesday, April 20
12:00 – 1:00 PM

Location
Nassau University Medical Center
East Meadow, NY

Confirmed Speaker
Shyam Kottilil, MD, PhD

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 1:00 pm – 2:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

1:00PM – 2:00PM ET

Please note this TeleECHO program is 1:00PM Eastern, 12:00PM, Central, 11:00AM Mountain and 10:00AM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Roger Bedimo, MD, MS
Professor of Medicine
University of Texas Southwestern Medical Center
Dallas, TX

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19
Apr 20 @ 5:00 pm – 6:00 pm

COVID-19 Frontline TeleECHO Series: A New Light in the Darkness: New Virus-neutralizing Monoclonal Antibodies and Other Point-of-Care Therapies Recently Granted Emergency Use Authorization for Patients with COVID-19

REGISTER FOR ECHO SESSION

Tuesday, April 20, 2021

5:00PM – 6:00PM ET

Please note this TeleECHO program is 5:00PM Eastern, 4:00PM, Central, 3:00PM Mountain and 2:00PM Pacific.

Program Features:

Project ECHO® is a lifelong learning and guided practice model that revolutionizes medical education and exponentially increases workforce capacity to provide best-practice specialty care and reduce health disparities. The heart of the ECHO model™ is its expansive knowledge-sharing network, led by expert teams who use multi-point videoconferencing to conduct virtual clinics with community providers. In this way, ECHO® fosters problem solving and interactive case discussion amongst doctors, nurses, and other clinicians, imparting invaluable insight to providing excellent specialty care to patients in their own communities.

The Project ECHO® format fosters dialogue and asking any questions you may have on the topic or a patient case in a HIPAA compliant manner is encouraged.

Program Overview:

The COVID-19 FRONTLINE TeleECHO series provides a comprehensive and up-to-date perspective on the ever-changing management of patients with COVID-19. Each TeleECHO session features in-depth case studies to encourage retention of the lessons and provide new perspectives on the management of patients during the COVID-19 pandemic. The case studies will focus on different issues facing clinicians, such as identifying  patients who would benefit from monoclonal antibody therapy and best practices for incorporating agents authorized for emergency use into the care of hospitalized and non-hospitalized patients with COVID-19. Strategies for administering neutralizing monoclonal antibodies, such as referral to local infusion centers or developing in-clinic infusion capabilities, will also be discussed.

Presenting Faculty:

Christopher Palma, MD, ScM
Assistant Professor of Medicine
University of Rochester
Rochester, NY

Learning Objectives

After completing the CME activity, learners should be better able to:

  • Assess the rationale for the use of neutralizing monoclonal antibody therapies in recently diagnosed COVID-19 patients to prevent the development of severe disease
  • Critique the efficacy and safety of new virus-neutralizing monoclonal antibody therapies and other therapies approved for emergency use in all patients who test positive for COVID-19
  • Develop in-clinic infusion capability in order to administer new virus-neutralizing monoclonal antibodies to patients with COVID-19 at the point-of-care

Target Audience

This CME initiative is designed for HCPs who are involved in the care and treatment of patients with COVID-19 in an outpatient setting, including physicians, NPs, PAs, nurses, pharmacists and paramedics.

Accreditation Statement

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 1.0 AMA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment of patients with COVID-19.

Credits:
1.0 ANCC Contact Hour

Accreditation Statement:

Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.

ABIM Maintenance of Certification 

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at [email protected]

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]

 

REGISTER FOR ECHO SESSION

 

Accreditation Statement
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Menu

Patient Toolkit

The COVID FRONTLINE Patient Toolkit is a resource center for patients who have been diagnosed with or who are interested in learning about COVID-19. Choose from the options below to learn more.

Clinical Toolkit

The COVID-19 Clinical Toolkit is an online tool that aims to provide clinicians with up-to-date information on the presentation, prognosis, pathophysiology, and treatment strategies for COVID-19. Click on one of the options below to learn more.

This activity is provided by Med Learning Group. This activity is co-provided by Ultimate Medical Academy/CCM.
This activity is supported by educational grants from AbbVie, Astellas, Genentech, Merck & Co., Inc., and Pfizer.

Copyright © 2019 | COVID Frontline | All Rights Reserved | Website by Divigner

Updates in the Treatment and Prevention of COVID-19​

First Single-Dose COVID-19 Vaccine Authorized for Emergency Use

On February 27, 2021, the US Food and Drug Administration (FDA) authorized a single-dose vaccine for emergency use to prevent COVID-19 in individuals 18 years of age and older. The FDA partly based its decision on data from the phase 3 EMSEMBLE trial, which was conducted in eight countries across three continents and included patients infected with emerging viral variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Data from this study demonstrated that the vaccine was 85% effective in preventing severe disease across all geographic regions studied. The level of protection against moderate and severe COVID-19 was 72% in the United States. The vaccine also provided protection against COVID-19-related hospitalization and death, beginning 28 days after vaccination. The Ad.26.COV2.S vaccine is a recombinant vector vaccine developed by the Janssen Pharmaceutical Companies of Johnson & Johnson that uses a human adenovirus to express the SARS-CoV-2 spike protein.

References:

National Institutes of Health (NIH). Janssen investigational COVID-19 vaccine: interim analysis of phase 3 clinical data released. January 29, 2021. Available at www.nih.gov/news-events/news-releases/janssen-investigational-covid-19-vaccine-interim-analysis-phase-3-clinical-data-released  Accessed 3/2/2021.

Johnson & Johnson COVID-19 vaccine authorized by U.S. FDA for emergency use—first single-shot vaccine in fight against global pandemic. February 27, 2021. Available at www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic  Accessed 3/2/2021.